Wegovy (semaglutide 2.4 mg) is an FDA-approved once-weekly injection that helps first responders achieve clinically significant weight loss of roughly 15% of body weight while also providing a 20% reduction in major cardiovascular events, making it arguably the most important medication available for a profession where heart attacks are the leading cause of on-duty death.

Why Wegovy Matters for First Responders

The intersection of obesity and cardiovascular risk in first response is not an abstract public health issue. It is a life-or-death operational concern:

• Cardiac deaths: Roughly 45% of on-duty firefighter fatalities are cardiac events.
• Obesity prevalence: 70% to 80% of firefighters and law enforcement officers are overweight or obese.
• Performance impact: Every excess pound reduces speed, endurance, and agility in gear.
• Career consequences: Failed fitness tests can result in restricted duty, lost overtime, or forced retirement.

Wegovy addresses both the weight and cardiovascular components of this problem, which is why it has gained significant traction in the first responder community.

How Wegovy Works

Wegovy contains semaglutide, a GLP-1 receptor agonist. It works through three mechanisms:

1. Appetite reduction: Acts on the hypothalamus to increase feelings of fullness and reduce hunger.
2. Gastric slowing: Delays stomach emptying so meals satisfy longer.
3. Insulin optimization: Improves blood sugar regulation and reduces insulin resistance.

The combined effect is a sustained, natural reduction in calorie intake without the hunger pangs and cravings that derail traditional diets.

Dosing for Shift Workers

Wegovy follows a 16- to 20-week titration:

1. Weeks 1 to 4: 0.25 mg
2. Weeks 5 to 8: 0.5 mg
3. Weeks 9 to 12: 1.0 mg
4. Weeks 13 to 16: 1.7 mg
5. Week 17+: 2.4 mg (maintenance)

Timing Your Injection

For first responders on rotating shifts, the key is consistency. Choose the same day each week and set a phone alarm. Many firefighters inject on their first off-duty day after a shift cycle. The time of day does not matter, only the seven-day interval.

Starting During Training or Light Duty

If possible, begin Wegovy during a period of lighter duty, vacation, or training assignment. The first four weeks at the initiation dose rarely cause significant side effects, but having buffer time lets your body adjust before returning to high-demand operational shifts.

Wegovy and Cardiovascular Protection

The SELECT trial enrolled over 17,000 overweight or obese adults without diabetes and demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo.

For first responders, this finding is transformative. It means Wegovy does not just help you lose weight. It actively protects your heart, regardless of whether you have diabetes. This dual benefit makes a compelling case for Wegovy as both a weight management and cardiac risk reduction tool.

On-Shift Considerations

Nutrition During 24-Hour Shifts

Wegovy significantly reduces appetite. During long shifts, this means:

• You can eat smaller firehouse meals without feeling deprived.
• Late-night snacking between calls becomes less tempting.
• You may need to remind yourself to eat enough to maintain energy for emergency response.

Tips for on-shift eating:

• Eat three structured meals even if appetite is low. Focus on protein and vegetables.
• Bring prepared snacks (jerky, nuts, protein bars) for sustained energy.
• Avoid relying solely on appetite cues. On a 24-hour shift, your body needs fuel regardless of hunger level.

Hydration

Dehydration is a critical risk for first responders, especially during fire suppression and summer operations. Wegovy can reduce thirst awareness and GI side effects may cause fluid loss. Drink at minimum 100 ounces of water daily and more during active operations.

Side Effect Management

Common side effects and duty-specific strategies:

• Nausea: Most common during dose increases. Eat bland, small meals. Keep ginger chews in your apparatus bag. Inject on your first off-duty day.
• GI changes: Diarrhea or constipation may occur. Stay near a bathroom during the first day after a dose increase.
• Fatigue: Occasional during the first week at a new dose. Usually resolves within days.
• Injection site reactions: Mild redness or itching. Rotate injection sites (abdomen, thigh, upper arm).

Fitness Standards and Performance

First responders using Wegovy should actively maintain physical performance:

• Resistance training: At least three sessions per week. Focus on deadlifts, squats, carries, presses, and pulling movements.
• Protein intake: 0.8 to 1.0 grams per pound of body weight. Protein shakes help when appetite is suppressed.
• Functional fitness: Continue CPAT-style training: stair climbs, hose drags, forcible entry simulation, victim rescue.
• Track progress: Monitor body composition, not just weight. DEXA scans or skinfold measurements can distinguish fat loss from muscle loss.

The good news: most first responders see improved fitness test performance as body weight decreases. Cardiovascular tasks become significantly easier at a lower weight.

Insurance and Cost

Wegovy costs approximately $1,300 per month at list price. $1,300-$1,400/mo (brand) First responder coverage options:

• Municipal health plans: Many cover Wegovy with prior authorization for BMI 30+ or BMI 27+ with comorbidities.
• Novo Nordisk savings card: Reduces copays for commercially insured patients. Contact provider for current pricing
• Union advocacy: IAFF and FOP locals are increasingly pushing for GLP-1 coverage as a cardiac risk reduction measure.
• Compounded semaglutide: Lower-cost alternative through compounding pharmacies. From $299

Department Policies

Wegovy is a legal, non-controlled prescription medication. It will not appear on drug tests and should not affect fitness-for-duty status. Follow standard medication disclosure requirements during annual physicals. Many department physicians are now actively recommending GLP-1 therapy for overweight first responders given the cardiac risk reduction evidence.